Doctor (The Chinese University of Hong Kong)

Bachelor (Southeast University)

Associate Professor Chang Zou received a bachelor of clinical medicine from Southeast University in 2002, and a doctorate from the School of Biomedicine of the Chinese University of Hong Kong in 2012. He is currently the deputy director of the Clinical Medicine Research Center of Shenzhen People’s Hospital, the leader of the outstanding youth cultivation team, and the deputy of the peak plan promotion office Director, visiting professor of the School of Pharmacy of Southwest Medical University, master tutor of Jinan University, Guangdong Medical University, Southern University of Science and Technology, Southwest Medical University and Guangxi Medical University, and postdoctoral supervisor of Jinan University. Shenzhen Municipal Talent, Guangdong Province Outstanding Young Medical Talent. Main research directions: 1) RNA modification and early tumor occurrence and drug resistance mechanisms; 2) Single cell and spatial transcriptomics analysis of tumor microenvironment; 3) Clinical translation and application of liquid biopsy technology. At present, he presides over 11 national natural science foundation and provincial and municipal key projects, and participates in 10 projects as the main finisher. Recently, as the first or corresponding author, he has published 61 articles in high-level journals such as Molecular Cancer, Journal of Experimental Medicine, Signal Transduct Target Ther, J Thorac Oncol, Autophagy, Pharmacol Ther, among which 14 articles have an impact factor of >10. He has applied for 25 invention patents, of which 15 have been authorized.

Corresponding author/Co-corresponding author：

1. Zhenwei Su#, Shaowei Dong#, Shan-Chao Zhao#, Kaisheng Liu, Yao Tan, Xingyu Jiang, Yehuda G. Assaraf, Bo Qin*, Zhe-Sheng Chen*, Chang Zou*. Novel nanomedicines to overcome cancer multidrug resistance. Drug Resistance Updates. 2021 Aug 4;58:100777.（Q1，IF=18.5）
2. Lin Gao#, Shanze Chen#, Malin Hong#, Wenbin Zhou#, Bilan Wan, Junying Qiu, Jinquan Xia, Pan Zhao, Li Fu, Jigang Wang, Yong Dai, Ni Xie, Qinhe Yang, Hsien-Da Huang, Xiang Gao*, Chang Zou*. Kinectin 1 promotes the growth of triple-negative breast cancer via directly co-activating NF-kappaB/p65 and enhancing its transcriptional activity. Signal Transduction and Targeted Therapy. 2021 Jul 5;6(1):250.（Q1，IF=18.18）
3. Jinan Guo#, Heather Johson#, Xuhui Zhang#, Xiaoyan Feng, Heqiu Zhang, Athanasios Simoulis, Alan HB Wu, Taolin Xia, Fei Li, Wanlong Tan, Allan Johnson, Nishtman Dizeyi, Per-Anders Abrahamsson, Lukas Kenner, Lingwu Chen, Wanmei Zhong, Kefeng Xiao, Jenny L. Persson*, Chang Zou*. A 23-gene classifier urine test for prostate cancer prognosis. Clinical and Translational Medicine.2021 Mar; 11(3): e340.（Q1，IF=11.494）
4. Xiaoshi Ma#, Jinan Guo#, Kaisheng Liu#, Lipeng Chen, Dale Liu, Shaowei Dong, Jinquan Xia, Qiaoyun Long, Yongjian Yue, Pan Zhao, Fengyan Hu, Zhangang Xiao, Xinghua Pan, Kefeng Xiao, Zhiqiang Cheng, Zunfu Ke*, Zhe-Sheng Chen*, Chang Zou*. Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing. Molecular Cancer 2020, 19:147. (Q1, IF=27.4)
5. Kaisheng Liu#, Lin Gao#, Xiaoshi Ma#, Juan-Juan Huang, Juan Chen, Lin Zeng, Charles R. Ashby Jr, Chang Zou*, Zhe-Sheng Chen*. Long non-coding RNAs regulate drug resistance in cancer. Molecular Cancer, 2020 Mar 12;19(1):54. (Q1, IF=27.4)
6. Huibin Song#, Dongcheng Liu#, Shaowei Dong#, Leli Zeng, Zhuoxun Wu, Pan Zhao, Litu Zhang, Zhe-Sheng Chen*, Chang Zou*. Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. Signal Transduct Target Ther. 2020 Sep 8;5(1):193. (Q1, IF=18.181)
7. Xiao Chen#, Yutong Wang#, Nan Ma#, Jing Tian, Yurou Shao, Bo Zhu, Yin Kwan Wong, Zhen Liang*, Chang Zou*, Jigang Wang*. Target Identification of Natural Medicine With Chemical Proteomics Approach: Probe Synthesis, Target Fishing and Protein Identification.Signal Transduct Target Ther. 2020 May 21;5(1):72. (Q1, IF=18.181)
8. Qingxin Zhou#, Meihua Lin#, Xing Feng#, Fei Ma#, Yuekun Zhu, Xing Liu, Chao Qu, Hong Sui, Bei Sun, Anlong Zhu, Heng Zhang, He Huang, Zhi Gao, Yongxiang Zhao, Jiangyun Sun, Yuxian Bai, Junfei Jin*, Xuehui Hong*, Chang Zou*, Zhiyong Zhang*. Targeting CLK3 inhibits the progression of cholangiocarcinoma by reprogramming nucleotide metabolism. Journal of Experimental Medicine. 2020 Aug 3;217(8):e20191779.（Q1, IF=14.301）
9. Feng Xing#, Zhang Heng#, Meng Lingbing#, Song Huiwen#, Zhou Qingxin, Qu Chao, Zhao Pan, Li Qinghua, Zou Chang*, Liu Xing*, Zhang Zhiyong*. Hypoxia-induced acetylation of PAK1 enhances autophagy and promotes brain tumorigenesis via phosphorylating ATG5. Autophagy; 2020 Mar, 18:1-20. （Q1, IF=16.014）
10. Zi-Ning Lei#, Zhuo-Xun Wu#, Shaowei Dong#, Dong-Hua Yang, Litu Zhang, Zunfu Ke*, Chang Zou*, Zhe-Sheng Chen*. Chloroquine and Hydroxychloroquine in the Treatment of Malaria and Repurposing in Treating COVID-19. Pharmacol Ther. 2020 Sep 7;216:107672. (Q1, IF=12.313)
11. Qijie Zhao#, Yueshui Zhao#, Wei Hu#, Yan Zhang#, Xu Wu, Jianwei Lu, Mingxing Li, Wei Li, Weiqing Wu, Jianhong Wang, Fukuan Du, Huijiao Ji, Xiao Yang, Zhenyu Xu, Lin Wan, Qinglian Wen, Xiang Li, Chi Hin Cho, Chang Zou*, Jing Shen*, Zhangang Xiao*. m6A RNA modification modulates PI3K/Akt/mTOR signal pathway in Gastrointestinal Cancer. Theranostics. 2020 Jul 25;10(21):9528-9543. (Q1, IF=11.550) 

First author/Co-first author:
1. Dan-Dan Liu#, Chang Zou#, Jianbin Zhang#, Peng Gao, Yongping Zhu, Yuqing Meng, Nan Ma, Ming Lv, Chengchao Xu, Qingsong Lin, Jigang Wang. Target Profiling of an Anticancer Drug Curcumin by an in situ Chemical Proteomics Approach. Methods in Molecular Biology. 2021;2213:147-161.
2. Jian Zhang#, Chang Zou#, Chenzhi Zhou#, Yifeng Luo#, Qiong He, Jianwen Zhou, Yu Sun, ZunfuKe*. IMAGE OF THE MONTH: A novel linc00308-21S2088E intergenic region-ALK fusion and ts enduring clinical responses to crizotinib. J Thorac Oncol.2020 Jun;15(6):1073-1077.（Q1, IF=15.601）
3. Ying Zhu#, Chang Zou#, Jian Zhang, Wenting Jiang, Fanglin Guan, Kejing Tang, Shuhua Li, Guannan Li, Jianhong Wang, Zunfu Ke. Dynamically Monitoring the Clonal Evolution of Lung Cancer Based on the Molecular Characterization of Circulating Tumor Cells Using Aptamer Cocktail-Modified Nanosubstrates. ACS Appl Mater Interfaces. 2020; 12(5): 5671-5679. （Q1, IF=9.244）
4. Xin Sun#, Peiyi Yan#, Chang Zou#, Yin-Kwan Wong#, Yuhan Shu, Yew Mun Lee, Chongjing Zhang, Nai-Di Yang, Jigang Wang*, Jianbin Zhang*. Targeting autophagy enhances the anticancer effect of artemisinin and its derivatives. Med Res Rev. 2019 Nov;39(6):2172-2193. （Q1, IF=12.492）
5. Chang Zou, Shan Yu, Zhenyu Xu, Dinglan Wu, Chi-Fai Ng, Xiaoqiang Yao, David T. Yew, Jean-Marc Vanacker and Franky L. Chan. ERRα augments HIF-1 signaling by directly interacting with HIF-1α in normoxic and hypoxic prostate cancer cells. J Pathol, 2014, 233(1): 61-73.（Q1, IF=7.991）